Specify a stock or a cryptocurrency in the search bar to get a summary
Protara Therapeutics Inc
TARAProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. Address: 345 Park Avenue South, New York, NY, United States, 10010
Analytics
WallStreet Target Price
26.4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TARA
Dividend Analytics TARA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TARA
Stock Valuation TARA
Financials TARA
Results | 2019 | Dynamics |